Observation on the Efficacy of the Combination of Edaravone and Butylphthalide in Patients with Acute Progressive Cerebral Infarction
Objective This study aims to investigate the therapeutic effect of combining Edaravone Dexacamphene with Butylphthalein in patients with acute progressive cerebral infarction.Methods A total of 150 patients with acute progressive cerebral infarction admitted to our hospital from May 2022 to May 2023 were selected as the research subjects.They were randomly divided into a control group and an observation group using a random number table method,with 75 cases in each group.The control group received sodium butylphthalide chloride treatment,while the observation group received a combination therapy of edaravone camphor and butylphthalide.Clinical efficacy,neurological function,hemorheological indicators,inflammatory cytokine levels,and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 92.00%higher than 80.00%of the control group,the difference was statistically significant(P＜0.05).After treatment,the observation group had lower scores on the National Institutes of Health Stroke Scale,whole blood high shear viscosity,whole blood low shear viscosity,and plasma viscosity than the control group,with statistically significant differences between the groups(P＜0.05);the average levels of tumor necrosis factor-α,high-sensitivity C-reactive protein,and interleukin-8 in the observation group were lower than those in the control group,the differences between the groups were statistically significant(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Combining edaravone and butylphthalide demonstrates definite efficacy in treating acute progressive cerebral infarction by improving neurological function and hemorheological indicators while reducing inflammatory reactions;moreover it exhibits high safety.
NETL
NSTL
万方数据
